跳至主要内容
临床试验/NCT00814177
NCT00814177已完成2 期

Management of Prothrombin Times Outside the Therapeutic Range in Patients on Warfarin and With Otherwise Stable Levels

Hamilton Health Sciences Corporation1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2006年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
160
试验地点
1
主要终点
Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks

研究概览

简要总结

Warfarin is very effective for the prevention of blood clots (thrombosis). A test of coagulation, the prothrombin time (PT) is used to monitor the effect. The PT response to warfarin can fluctuate as a result of interactions with a large number of other drugs, food or herbal agents as well as for no apparent reason. Thus, frequent monitoring of the PT and dose adjustments according to the results are required. One third of our patients remain on the same maintenance dose over 6 months. However, also these patients sometimes have a PT result moderately outside the therapeutic range without any obvious explanation. Too short PTs may be due to missed dose(s) or more dark green vegetables in the diet. Too long PTs may be due to a course of antibiotic therapy or less dark green vegetables. Laboratory errors may also occur and can cause deviations in any direction. Most likely, unnoticed fluctuations in the PT occur as well between the time points of monitoring.

There are no guidelines on how to manage the treatment in this situation but there are some typical "behaviours".

Behavior A: Some physicians simply let the patient continue with the same dose. "It is extremely unlikely that the very temporary dose adjustment has any effect on the PT result 4 weeks later and this is a "cosmetic procedure"." Behavior B: Others recommend the patients to take ½ - 1 additional dose in case of short PT and to skip a dose or take half dose in case of long PT, and thereafter to continue with the usual dose. "The investigators need to quickly correct the temporary aberration in order to avoid thrombotic or bleeding complications the next few days.

This may seem like an issue of no importance. The investigators are however performing a series of studies to evaluate if these stable patients can be managed with blood tests less often than every 4 weeks. For that purpose it is important to know how often and why aberrant results occur, the implication and to what extent they can be ignored.

The investigators hypothesis is that in patients with very stable PT-results and unchanged dose for 3 months, should continue with exactly the same maintenance dose, even when the result unexpectedly is slightly above or below the therapeutic range. The investigators believe that most of these occasional PT-results outside the therapeutic range are due to laboratory errors, perhaps missed doses by the patient or temporary change in diet or medications.

详细描述

Setting:

Thrombosis Service at HHS - General Hospital. This center monitors the warfarin treatment for 1300 patients in the region. These patient regularly go to a laboratory where they live. Test results (INR-results) are faxed to the Thrombosis Service, which calls the patient the same day to inform them of the results, how to continue dosing the warfarin and when to go for the following blood test.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients on long-term warfarin (for prophylaxis of arterial embolism in patients with atrial fibrillation or mechanical heart valve replacement, or secondary prophylaxis after VTE) with a target INR of 2.0-3.0 or 2.5-3.5,
  • Anticoagulant therapy managed by the clinic (HHS - General Hospital) for at least 3 months prior to enrolment, and
  • Maintenance dose of warfarin unchanged for the previous 3 months or longer.
  • The INR result is outside the therapeutic range as follows:
  • For those with target 2.0-3.0: Either an INR of 1.5-1.9 or an INR of 3.1-4.
  • For those with target 2.5-3.5: Either an INR of 1.5-2.4 or an INR of 3.6-4.4.

排除标准

  • Age <18 years,
  • Long-term (>1 week) change in any other medication
  • Long-term (>1 week) change in diet, especially regarding green vegetables.
  • Attending physician believes the patient is not suitable for the study (e.g. psychiatric disorder, history of non-compliance),
  • Failure to obtain telephone consent.

研究组 & 干预措施

No change

Experimental

Intervention Drug warfarin no change in the dose is performed

干预措施: warfarin (Drug)

Change

Active Comparator

Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level

干预措施: warfarin (Drug)

结局指标

主要结局

Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks

时间窗: 2 weeks

The number of patients with "follow-up INRs" within the therapeutic range was compared for patients with a single dose skipped/reduced/added versus patients with no change of dose.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sam Schulman

Professor, MD

McMaster University

研究点 (1)

Loading locations...

相似试验

Prothrombin Times Outside the Therapeutic Range in... | 临床试验